This invention is a new anti-cancer peptide for treatment of Triple-Negative Breast Cancer. The new peptide focuses on blocking of Epidermal Growth Factor Receptor (EGFR), which allows for increased M1 macrophage polarity and decreased M2 macrophage polarity. M1 polarized macrophages are associated with tumor regression and an active anti-cancer immune response. Background: Triple-Negative Breast Cancer refers to a type of cancer with cells that don’t have estrogen or progesterone receptors (ER or PR) and fail to adequately produce the protein called HER2. This subset of breast cancer is representative of 10-15% of all breast cancer diagnosis, where patients are at higher risk for worse disease specific outcomes than typical breast cancer patients. The use of Paclitaxel as a taxane approach, or a PARP inhibitor such as Olaparib has been the standard method of treatment of Triple-Negative Breast Cancer for the last decade. This new method of treatment utilizes a peptide with the ability to influence macrophage polarity in order to increase tumor suppression and immune response. Applications:
Advantages: